Key result
Postdischarge extended clinical pharmacist follow-up fails to reduce 90-day readmissions versus standard of care.
Why the study?
Data are limited regarding the effect of clinical pharmacist follow-up on 90-day readmissions and disease-specific clinical goals after hospitalization.
Does postdischarge extended clinical pharmacist follow-up reduce all-cause 90-day readmission rates in patients discharged from a family medicine service?
Population
Patients admitted August 2016 to November 2017 seen by an FMS physician within 14 days postdischarge
Comparison
Postdischarge extended clinical pharmacist follow-up vs standard of care
Design
Retrospective chart review
Follow-up
90 days
Authors
Loading...
Extended CP follow-up may lower 90-day readmissions; leaves open confirmation in prospective trials of disease-specific outcomes.
Cohort
Does postdischarge extended clinical pharmacist follow-up reduce all-cause 90-day readmission rates in patients discharged from a family medicine service?
Absolute Event Rate: 14% vs 22%
p-value: p=.244
Postdischarge extended clinical pharmacist follow-up did not significantly reduce 90-day readmission rates, although it showed a significant reduction in 30-day readmissions.
Wiegmann et al. (2019) conducted a cohort in Hospitalized patients discharged to a family medicine service. Postdischarge extended clinical pharmacist follow-up vs. Standard of care was evaluated on All-cause 90-day readmission rates (p=.244). Postdischarge extended clinical pharmacist follow-up did not significantly reduce all-cause 90-day readmission rates compared to standard of care (14% vs 22%, P=0.244).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: